The therapy met both primary and secondary end points across a broad spectrum of patients with generalized myasthenia gravis, including significant reductions in both QMG and MG-ADL scores.
The director of the epilepsy center at Cleveland Clinic spoke about the process that leads to the selection of candidacy for deep brain stimulation.  

SAP Partner Banner